Identification of patients with advanced pancreatic cancer who might benefit from third-line chemotherapy

doi:10.4251/wjgo.v17.i2.100167

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (153)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-4) series.

Item

Count

PDF

HTML

Figures (1-3)

Tables (1-4)

Sum=80

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=48

Publishing Process of This Article

Item

Count

Browse

Download

Sum=20

Feb 15, 2025 (publication date) through Jan 20, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Oncol. Feb 15, 2025; 17(2): 100167
Published online Feb 15, 2025. doi: 10.4251/wjgo.v17.i2.100167

Table 1 Baseline characteristics, n (%)

		Third-line chemotherapy (n = 141)	Best supportive care (n = 167)	P value
Mean age (year, range)		61.8 (36.0-86.0)	59.5 (21.0-81.0)	0.200
Gender	Male	78 (54.9)	102 (61.1)	0.277
Initial tumor location	Head/body/tail	51/45/45 (36.6/31.7/31.7)	68/42/57 (40.7/25.2/34.1)	0.011
Initial stages	Locally advanced/metastatic	32/109 (22.5/76.8)	60/106 (36.1/63.9)	0.010
Initial metastatic lesions	Liver/peritoneum/other	74/36/56 (67.9/37.0/51.4)	70/32/22 (41.9/19.2/13.2)	< 0.001
Median CA19-9 before (U/mL) (SD)	First-/second-/third-line CTx	450/655/1820 (9231.4/7865.2/10901.9)	330/480/NA (8447.3/8257.0/NA)	0.248/0.298/NA
CA19-9 before third-line CTx (n = 134)	< 1000/≥ 1000 U/mL	49/85 (36.6/63.4)
First-line regimen	FOLFIRINOX/GNP	95/46 (67.4/32.6)	122/45 (73.1/26.9)	0.241
Second-line regimen	FOLFIRINOX/GNP/TS-1/nal-IRI plus 5FU and leucovorin/other	38/74/3/8/18 (27.0/52.5/2.1/5.7/12.8)	36/110/9/5/7 (21.6/65.9/5.4/3.0/4.2)	< 0.001
Third-line regimen	TS-1/nal-IRI plus 5FU and leucovorin/other	68/53/20 (48.2/37.6/14.2)
Median duration (week)	First/second-line CTx	27.2/16.0 (29.0/15.9)	27.4/11.9(46.3/19.7)	0.797/0.800
Duration of second-line CTx	< 19 weeks/≥ 19 weeks	89/52 (63.1/36.9)	127/30 (80.9/19.1)	< 0.001
Median relative dose	First-/second-/third-line CTx	74/78/100 (0.18/0.17/0.19)
PS after second-line CTx	Good/intermediate/poor	118/23/0 (83.7/16.3/0.0)	3/69/95 (1.8/41.3/56.9)	< 0.001

SD: Standard deviation; NA: Not available; CTx: Chemotherapy; CA19-9: Carbohydrate antigen 19-9; FOLFIRINOX: 5-fluorouracil/leucovorin, irinotecan, and oxaliplatin; GNP: Gemcitabine plus nab-paclitaxel; TS-1: Titanium silicate-1; 5FU: 5-fluorouracil; nal-IRI: Nano-liposomal irinotecan; PS: Performance status.

Citation: Kim B, Kim J, Yang S, Ahn J, Jung K, Lee JC, Hwang JH. Identification of patients with advanced pancreatic cancer who might benefit from third-line chemotherapy. World J Gastrointest Oncol 2025; 17(2): 100167
URL: https://www.wjgnet.com/1948-5204/full/v17/i2/100167.htm
DOI: https://dx.doi.org/10.4251/wjgo.v17.i2.100167